Article in Dagens Industri Invest Talks, March 2021
With its powerful and versatile platform, Beactica Therapeutics identifies innovative small molecule drug candidates that have a targeted effect against carefully selected disease proteins. Strategic collaborations provide access to valuable knowledge and opportunities to work with a broader portfolio. We speak to the company's CEO, Dr Per Källblad.
Sign up for the Beactica newsletter to receive our latest news and updates